Chief Executive Officer Lamberto Andreotti

Chief Executive Officer Lamberto Andreotti

Daniel Acker/Bloomberg

Chief Executive Officer Lamberto Andreotti called 2012 a transition year for Bristol-Myers because it lost exclusive U.S. sales rights for its top-selling blood thinner Plavix and must begin to rely on new products such as its skin-cancer drug Yervoy.